



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/719,552	11/21/2003	Are Bogsnes	5432.220-US	3561
23650	7590	05/09/2006	EXAMINER	
NOVO NORDISK, INC.				KAM, CHIH MIN
PATENT DEPARTMENT				ART UNIT
100 COLLEGE ROAD WEST				PAPER NUMBER
PRINCETON, NJ 08540				1656

DATE MAILED: 05/09/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/719,552	BOGSNES, ARE
	Examiner	Art Unit
	Chih-Min Kam	1656

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 24 February 2006.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1 and 2 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1 and 2 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on 21 November 2003 is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. 09/290,856.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ .

5) Notice of Informal Patent Application (PTO-152)

6) Other: ____ .

DETAILED ACTION

Status of the Claims

1. Claims 1-2 are pending.

Applicants' amendment filed February 24, 2006 is acknowledged, and applicants' response has been fully considered. Claim 1 has been amended. Thus, claims 1-2 are examined.

Withdrawn Claim Rejections - 35 USC § 102

2. The previous rejection of claims 1-2 under 35 U.S.C. 102(b) as being anticipated by Thim *et al.* (EP 0195691), is withdrawn in view of applicants' amendment to the claim, and applicant's response at page 3 in the amendment filed February 24, 2006.
3. The previous rejection of claims 1-2 under 35 U.S.C. 102(b) as being anticipated by Kjeidsen *et al.* (U. S. Patent 6,214,547), is withdrawn in view of applicants' amendment to the claim, and applicant's response at page 3 in the amendment filed February 24, 2006.

New Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 1 and 2 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1 and 2 are directed to a composition comprising an insulin component consisting of recombinant insulin or an analog thereof, wherein the insulin component contains 0.02% to

0.2% glycosylated insulin or insulin analog, the remainder being unglycosylated insulin or insulin analog, and the recombinant insulin or insulin analog is produced in a yeast cell. While the specification describes the separation of glycosylated insulins from non-glycosylated insulins, and the concentration of glycosylated insulins in the fraction of non-glycosylated insulin can be less than 0.2 % such as less than 0.1% (page 5, lines 21-26; page 7, lines 6-10); Example 3 indicates the content of monoglycosylated decreased to 0.02% after the purification of a fraction of non-glycosylated insulin; and Example 4 indicates purification of desB30 using buffer system with CaCl_2 would reduce mono-glycosylated desB30 to 0.21%, the specification has not described a composition comprising an insulin component, wherein the insulin component contains “0.02% to 0.2%” glycosylated insulin or insulin analog. Furthermore, there are no working examples indicating the purification procedure would produce a composition comprising an insulin component, wherein the insulin component contains “0.02% to 0.2%” glycosylated insulin or insulin analog. The lack of description of a composition comprising an insulin component, wherein the insulin component contains 0.02% to 0.2% glycosylated insulin or insulin analog, and the lack of representative species for the composition containing an insulin component having 0.02% to 0.2% glycosylated insulin or insulin analog as encompassed by the claims, applicants have failed to sufficiently describe the claimed invention, in such full, clear, concise terms that a skilled artisan would not recognize applicants were in possession of the claimed invention.

Conclusion

5. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr can be reached at 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chih-Min Kam, Ph. D.
Patent Examiner



CHIH-MIN KAM
PATENT EXAMINER

CMK

May 4, 2006